COCP · Cocrystal Pharma, Inc.
$1.09
-0.03 (-2.68%)
At close · Aug 17
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“For the six months ended June 30, 2026, the Company recorded a net loss of approximately $5,463 and used approximately $4,856 of cash in operating activities. These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$21.38M
Shares
19.26M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-08-17 | — | |
| 10-Q | 2026-08-13 | 2026-06-30 | |
| 8-K | 2026-08-03 | 2026-07-31 | |
| 8-K | 2026-07-17 | 2026-07-14 | |
| 8-K | 2026-06-09 | 2026-06-03 | |
| 8-K | 2026-06-03 | — | |
| DEF 14A | 2026-05-27 | — | |
| 8-K | 2026-05-26 | — | |
| 10-Q | 2026-05-15 | 2026-03-31 | |
| 8-K | 2026-04-30 | — | |
| 8-K | 2026-04-02 | — | |
| 10-K | 2026-03-31 | 2025-12-31 | |
| 8-K | 2026-03-31 | — | |
| 8-K | 2026-03-13 | 2026-03-10 | |
| 8-K | 2026-03-09 | — | |
| 8-K | 2026-02-19 | — | |
| 8-K | 2026-01-15 | 2026-01-09 | |
| 8-K | 2025-12-18 | — | |
| 8-K | 2025-12-01 | — | |
| 8-K | 2025-11-14 | — | |
| 10-Q | 2025-11-14 | 2025-09-30 | |
| 8-K | 2025-10-30 | 2025-10-28 | |
| 8-K | 2025-10-27 | — | |
| 8-K | 2025-09-15 | 2025-09-12 | |
| 8-K | 2025-09-12 | — | |
| 8-K | 2025-09-12 | — | |
| 10-Q | 2025-08-14 | 2025-06-30 | |
| 8-K | 2025-08-14 | — | |
| 8-K | 2025-08-05 | — | |
| 8-K | 2025-07-10 | — | |
| 8-K | 2025-07-01 | 2025-06-25 | |
| 8-K | 2025-06-18 | 2025-06-17 | |
| 8-K | 2025-06-05 | — | |
| 8-K | 2025-05-29 | — | |
| 8-K | 2025-05-15 | — | |
| 10-Q | 2025-05-15 | 2025-03-31 | |
| DEF 14A | 2025-05-05 | — | |
| 8-K | 2025-04-24 | — | |
| 8-K | 2025-04-23 | — | |
| 8-K | 2025-04-08 | 2025-04-02 | |
| 8-K | 2025-04-01 | 2025-03-31 | |
| 8-K | 2025-03-31 | — | |
| 10-K | 2025-03-31 | 2024-12-31 | |
| 8-K | 2025-01-13 | — | |
| 8-K | 2025-01-08 | — | |
| 8-K | 2024-12-31 | — | |
| 10-Q | 2024-11-13 | 2024-09-30 | |
| 8-K | 2024-11-13 | — | |
| 8-K | 2024-10-31 | — | |
| 8-K | 2024-10-10 | 2024-10-09 |
Showing 1–50 of 147 filings
Key facts
CIK
1412486
CUSIP
19188J409
13F (30d)
29 filings
29 filers
Visit website
Investor relations